MilliporeSigma Announces Collaboration with Innovative Biotech to Support Establishment of First Vaccine Production Facility in Nigeria

Our Life Science business sector has signed an agreement with biotechnology company Innovative Biotech (IB) to design the manufacturing process for the first vaccine production facility in Nigeria.

14 Dec 2021 | Lagos, Nigeria
  • Supports West African pandemic readiness program
  • Accelerates self-sufficient vaccine development and manufacturing in West Africa

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the Life Science business sector has signed an agreement with biotechnology company Innovative Biotech (IB) to design the manufacturing process for the first vaccine production facility in Nigeria.

“We are committed to expanding access to life-saving and life-enhancing therapies to patients across the world and this collaboration is a testament to that commitment,” said Andrew Bulpin, Head of Process Solutions, Life Science business sector. “We are proud to provide the technical support and expertise that could help enable the first vaccine facility in Nigeria and localize vaccine development in the West Africa region.”

This collaboration is part of the West African pandemic readiness program, which aims to localize vaccine development in the African nations. The first phase of this integrated partnership focuses on designing the fill and finish facility, incorporating Mobius® single-use technology offered by the Life Science business sector, while the second phase will focus on enabling continuous manufacturing.

“By leveraging facility design expertise of the Life Science business sector, we’ll be able to build the first vaccine production facility in Nigeria and manufacture high-quality and affordable vaccines locally,” said Simon Agwale, CEO of Innovative Biotech.

Innovative Biotech’s licensor, TechnoVax, is developing a virus-like-particle (VLP)-based vaccine to target variants of Covid-19. Provisional results from the preclinical studies of the VLP-based vaccine have shown promise for virus neutralization. Technovax is a 2019 recipient of MilliporeSigma’s Advance Biotech Grant for developing a virus-like particle platform that facilitates the development and production of a range of vaccines targeting the prevention of respiratory diseases, hemorrhagic fevers, immunodeficiency and cancers.

The Life Science business sector has been supporting Innovative Biotech’s effort with its BioReliance® testing services, technical transfer support and single-use facility design. This partnership showcases the Life Science business sector’s commitment to supporting the building of manufacturing capabilities in the Middle East and Africa.

Downloads

For more information, please contact Rachel Bloom-Baglin

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About the Life Science business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 23,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany, generated sales of € 17.5 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service. 

Related News

  1. Press Releases

    MilliporeSigma Opens US$ 65 Million CDMO Facility to Address Demand for Critical ...

    MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of ...

    2022/06/23